Detailed price information for Mirum Pharmaceuticals Inc (MIRM-Q) from The Globe and Mail including charting and trades.

LFTs are a panel of blood tests that help detect liver injury, cholestasis or synthetic dysfunction. Learn what each marker ...

Gilead Sciences, Inc. (Nasdaq: GILD) will present new research that reinforces its commitment to advancing innovation for ...

Obeticholic acid added to ursodeoxycholic acid improved alkaline phosphatase and bilirubin levels among patients with PBC unresponsive to first-line therapy.

Health Canada has granted conditional approval for Gilead Sciences’ Lyvdelzi (seladelpar) for adults with primary biliary ...

CNW/ - Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Health Canada has approved LYVDELZI (seladelpar) for the ...

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies ...

Proqr Therapeutics NV has received clinical trial application (CTA) authorization under the EMA’s new centralized review ...

A Selkirk woman living with a disability says she’s spent more than a year fighting Manitoba’s income support system over ...

Morgan Stanley raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $81 from $75 and keeps an Overweight rating on the shares. For ...

MIRM's Livmarli remains its dominant growth engine and is expected to have boosted its top line in the third quarter.